Articles tagged with Akt Inhibitors
Researchers discovered a molecular link between multicentric carpotarsal osteolysis (MCTO) and kidney disease, highlighting pathogenic MAFB accumulation and PI3K/AKT signaling. Treatment with imatinib suppressed AKT phosphorylation and attenuated glomerular injury in mice.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
Researchers from Okayama University found that Actinidia arguta (Sarunashi) juice and its component isoquercetin inhibit lung cancer development in mice, accelerating DNA repair and suppressing Akt-mediated growth signaling. The study suggests Sarunashi juice as an attractive candidate for chemoprevention.
In a patient trial, the AKT inhibitor ipatasertib showed signs of effectiveness in treating advanced cancers. 22% of patients experienced tumor shrinkage, while 56% had stable disease. Further research is needed to understand why some patients responded and others did not.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
Researchers at UC San Diego have developed a reliable method to culture human sperm stem cells, overcoming a key bottleneck in SSC therapy. The approach uses AKT inhibitors to maintain the growth of immature germ cells with SSC characteristics, paving the way for potential clinical applications.
Researchers found TLR4 signaling increases apoptotic ratio in hippocampal neurons stimulated by lipopolysaccharide. Inhibiting AKT and GSK-3β pathways decreases active Caspase-3 and Bax/Bcl-2 ratios, suggesting a new target for neurodegenerative disease treatment.
Researchers discover that rapamycin blocks abnormal tumor-like blood vessel formation by inhibiting Akt signaling, a key player in tumor growth. This finding suggests a potential clinical utility for rapamycin as an anti-angiogenic agent and opens up a new pathway for rapamycin's therapeutic action.
Researchers discovered AKT paradoxically blocks cancer cell motility and invasion abilities, preventing cancer spread. The study's findings suggest targeting AKT may increase cells' properties of motility and invasiveness.